The Cost of Breast Cancer Surgery – Is the Money Spent Reflected on Health-related Quality of Life?

• Published in: In vivo (Athens) Vol. 36; no. 5; pp. 2279 - 2286
• Main Authors: RAUTALIN, MERVI, JAHKOLA, TIINA, ROINE, RISTO P.
• Format: Journal Article
• Language: English
• Published: International Institute of Anticancer Research 01.09.2022
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.12957

BACKGROUND/AIMDifferent treatment options of breast cancer (BC) are dependent on certain cancer- and patient-related features. The cost of treatment varies among patients. This study describes the cost distribution in the treatment of Finnish patients with BC for two years and relates the costs to important outcomes of modern BC treatment. PATIENTS AND METHODSHealth-related quality of life (HRQoL) of 1,065 patients was measured prospectively at baseline, and 3, 6, 12, and 24 months thereafter with a generic (15D) and a disease-specific (EORTC QLQ C-30 BR23) HRQoL-instrument. Clinical data and costs of care were collected from hospital records. Patients were divided into four groups according to the surgical approach: breast-conserving surgery (BCS n=661), mastectomy (n=319), immediate reconstruction (IBR n=51), and delayed reconstruction (DR n=34), and the costs according to the clinic responsible for treatment: oncological-, breast surgery-, and plastic surgery unit. Total costs of care during follow-up are presented groupwise alongside HRQoL results. RESULTSThe mean total cost for BC surgery was 6,015 Euros for BCS, 8,114 euros for mastectomy, 18,217 Euros for IBR, and 19,041 Euros for DR. BCS, IBR, and DR produced good HRQoL. Mastectomy patients had the lowest overall HRQoL and highest cost accumulation at the oncology unit. HRQoL of IBR and DR patients was similar. CONCLUSIONDR produces good HRQoL but generates the highest costs of care. If patients that require reconstruction could be identified earlier and offered IBR instead of mastectomy followed by later DR, the costs of care might be reduced.